KliRNA Biotech

Name

KliRNA Biotech

Legal name

KliRNA Biotech

Website

https://klirna.com

Company type

Private

Operating status

Acquired

Short description

KliRNA Biotech is a pre-clinical subsidiary of Alys Pharmaceuticals developing antipruritic therapies that target neuronal molecular switches of itch to treat chronic pruritic conditions. No disclosed products, revenue, or headcount are available.

Ownership category

akta.pro rank

Product category

Antipruritic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Antipruritic therapeutics
• Itch treatment biotech
• Neuronal molecular switches
• Chronic itch therapies
• Biotech drug development

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

KliRNA Biotech develops pharmaceutical treatments that target neuronal molecular switches of itch to deliver broad-spectrum, long-term antipruritic (anti-itch) therapies. The company focuses on addressing the underlying neurological mechanisms of itch rather than providing only symptomatic relief. KliRNA Biotech is now a fully owned subsidiary of Alys Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Alys PharmaceuticalscoreStrategic or Co-development PartnerKliRNA Biotech is now a fully owned subsidiary of Alys Pharmaceuticals. This represents a corporate acquisition/merger relationship where KliRNA operates as part of the Alys Pharmaceuticals organization, likely contributing its neuronal molecular switch technology platform to the parent company's pipeline.

Direct peers

• Ionis Pharmaceuticals: Leading antisense oligonucleotide (ASO) therapeutics company with neurological pipeline assets. Comparable RNA-targeting modality and experience with CNS/peripheral neural target engagement.
• Arrowhead Pharmaceuticals: Clinical-stage siRNA therapeutics company with broad pipeline including CNS-directed programs. Same RNA-targeting modality and similar platform-style biotech structure.
• Alys Pharmaceuticals: Parent company and acquirer of KliRNA Biotech, focused on antipruritic therapeutics. Provides direct comparability in indication, mechanism philosophy (targeting underlying pruritus biology), and target patient population.
• Trevi Therapeutics: Clinical-stage biotech focused on chronic pruritus therapeutics (Haduvio/nalbuphine ER for prurigo nodularis and refractory chronic cough). Most direct indication peer given shared chronic-itch patient population and similar antipruritic positioning.
• Arcutis Biotherapeutics: Dermatology-focused commercial biotech with topical anti-inflammatory therapies for skin conditions with significant itch components (e.g., Zoryve in atopic dermatitis, seborrheic dermatitis). Comparable indication overlap and dermatology/skin-driven pruritus patient base.
• Alnylam Pharmaceuticals: Leading commercial-stage RNAi therapeutics company (siRNA platform) — directly comparable modality peer since KliRNA's name and mechanism imply an RNA-based approach. Validates that RNA platforms can achieve clinical and commercial scale.

Emerging players

• Wave Life Sciences: Clinical-stage RNA editing / RNAi therapeutics company with programs in CNS and neurological indications. Comparable RNA modality applied to neural targets; emerging player with partial overlap in approach.
• ProQR Therapeutics: Emerging clinical-stage RNA therapeutics company developing antisense oligonucleotides for rare genetic diseases. Comparable RNA-targeting modality; emerging player with more limited pipeline overlap.

Broad incumbents

• Galderma: Global dermatology-focused pharmaceutical company with commercial franchises in skin conditions where itch is a primary symptom (atopic dermatitis, rosacea). Comparable patient population and indication, broader portfolio incumbent.
• Sanofi Regeneron (Dupixent): Dupixent (dupilumab, IL-4/IL-13) is the leading biologic for atopic dermatitis and associated chronic pruritus. Represents the dominant immune-mediated anti-itch therapeutic and primary competitive incumbent in the chronic-itch space KliRNA targets.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KliRNA Biotech